-
Semaglutide (Ships to You)
Regular price $297.00 USDRegular priceUnit price per$399.00 USDSale price $297.00 USDSale -
Tirzepatide (Month 2+)
Regular price $589.00 USDRegular priceUnit price per -
Lipo (MIC) Injections
Regular price $169.00 USDRegular priceUnit price per -
Sermorelin Peptide
Regular price $299.00 USDRegular priceUnit price per -
Tirzepatide (Mounjaro® and Zepbound™ active ingredient)
Regular price $348.00 USDRegular priceUnit price per$499.00 USDSale price $348.00 USDSale -
LDN (Low-Dose Naltrexone)
Regular price $117.00 USDRegular priceUnit price per$195.00 USDSale price $117.00 USDSale -
Sale
Tirzepatide
Regular price $348.00 USDRegular priceUnit price per$499.00 USDSale price $348.00 USDSale -
Thermo-Suppress Supplements
Regular price $79.00 USDRegular priceUnit price per
Sources:
[1] World Health Organization. (2020). Obesity and overweight. Retrieved from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
[2] Centers for Disease Control and Prevention. (2020). Benefits of healthy weight. Retrieved from https://www.cdc.gov/healthyweight/effects/index.html
[3] Fontaine, K. R., Barofsky, I., Andersen, R. E., Bartlett, S. J., Wiersema, L., Cheskin, L. J., & Franckowiak, S. C. (1999). Impact of weight loss on health-related quality of life. Quality of Life Research, 8(3), 275-277.
[4] Velloso, C. P. (2008). Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology, 154(3), 557-568.
[5] Holstein, J. D., & Griffin, J. C. (2018). Lipo-C (Lipotropic) Injections for Weight Loss: A Review of the Literature. Journal of Nutritional Science and Vitaminology, 64(4), 287-291.
[6] van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. (2014). Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International journal of obesity, 38(6), 784-793.
[7] Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., ... & Seufert, J. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.